# 1 Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-

#### 2 free DNA.

- 3
- 4 Grace Lisius<sup>1</sup>, Radha Duttagupta<sup>2</sup>, Asim A. Ahmed<sup>2</sup>, Matthew Hensley<sup>3</sup>, Nameer Al-Yousif<sup>4</sup>, Michael Lu<sup>1</sup>,
- 5 William Bain<sup>3,5,6</sup>, Faraaz Shah<sup>3,5</sup>, Caitlin Schaefer<sup>3,5</sup>, Shulin Qin<sup>3,7</sup>, Xiaohong Wang<sup>3</sup>, Yingze Zhang<sup>3,5</sup>, Kevin J.
- 6 Mitchell<sup>8</sup>, Ellen K. Hughes<sup>8</sup>, Jana L. Jacobs<sup>9</sup>, Asma Naqvi<sup>9</sup>, Ghady Haidar<sup>9</sup>, John W. Mellors<sup>9</sup>,
- 7 Barbara Methé<sup>3,7</sup>, Bryan J. McVerry<sup>3,5,7</sup>, Alison Morris<sup>3,7</sup>, Georgios D. Kitsios<sup>3,5,7</sup>
- 8
- 9 <sup>1</sup>Internal Medicine Residency Program, UPMC, Pittsburgh, PA;
- 10 <sup>2</sup>Karius Inc, Redwood City, CA;
- <sup>3</sup>Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA;
- <sup>4</sup>Internal Medicine Residency Program, UPMC Mercy, Pittsburgh, PA;
- 13 <sup>5</sup>Acute Lung Injury Center for Excellence, Division of Pulmonary, Allergy and Critical Care Medicine, University
- 14 of Pittsburgh, Pittsburgh, PA;
- <sup>15</sup> <sup>6</sup>Veterans Affairs Pittsburgh Health System, Pittsburgh, PA;
- <sup>7</sup>Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, PA;
- 17 <sup>8</sup>Computer Vision Group, Veytel LLC, Pittsburgh, PA;
- <sup>9</sup>University of Pittsburgh School of Medicine, Division of Infectious Diseases, Pittsburgh, PA.
- 19
- 20 Corresponding Author:
- 21 Georgios D. Kitsios, MD, PhD
- 22 Assistant Professor of Medicine
- 23 Division of Pulmonary, Allergy and Critical Care Medicine
- 24 University of Pittsburgh Medical Center
- Address: UPMC Montefiore Hospital, NW628, 3459 Fifth Avenue, Pittsburgh, PA 15213
- 26 Email: <u>kitsiosg@upmc.edu</u>
- 27 **Summary of conflict-of-interest statements**: Drs. Duttagupta and Ahmed are employed by Karius, Inc. Dr.
- 28 Kitsios, Dr. Haidar have received research funding from Karius, Inc in 2018-2019. Dr. Mellors is a consultant to

- 29 Gilead Sciences and owns shares or share options in Co-Crystal Pharmaceuticals, ID Connect, and Abound
- 30 Bio, all unrelated to the current work. Dr. McVerry has received research funding from Bayer Pharmaceuticals,
- 31 Inc. and consulting fees from Boehringer Ingelheim, both unrelated to this work. All other authors disclosed no
- 32 conflict of interest.
- 33 Funding information: Dr. Kitsios: University of Pittsburgh Clinical and Translational Science Institute, COVID-
- 34 19 Pilot Award; NIH (K23 HL139987; R03 HL162655). Dr. Bain: Career Development award number IK2
- 35 BX004886 from the U.S. Department of Veterans Affairs Biomedical Laboratory R&D (BLRD) Service. Caitlin
- 36 Schaefer: NIH (P01 HL114453).

#### 37 Abstract:

- 38 Background: Secondary infection (SI) diagnosis in COVID-19 is challenging, due to overlapping clinical
- 39 presentations, practical limitations in obtaining samples from the lower respiratory tract (LRT), and low
- 40 sensitivity of microbiologic cultures.
- 41 <u>Research Question</u>: Can metagenomic sequencing of plasma microbial cell-free DNA (mcfDNA-Seq) help
- 42 diagnose SIs complicating COVID-19?

43 Study Design and Methods: We enrolled 42 inpatients with COVID-19 classified as microbiologically-confirmed

- 44 SI (Micro-SI, n=8), clinically-diagnosed SI (Clinical-SI, n=13, i.e. empiric antimicrobials), or no clinical suspicion
- 45 for SI (No-Suspected-SI, n=21) at time of enrollment. From baseline and follow-up plasma samples (days 5
- 46 and 10 post-enrollment), we quantified mcfDNA for all detected microbes by mcfDNA sequencing and
- 47 measured nine host-response biomarkers. From LRT samples among intubated subjects, we quantified
- 48 bacterial burden with 16S rRNA gene quantitative PCR.
- 49 <u>Results</u>: We performed mcfDNA-Seq in 82 plasma samples. Sequencing was successful in 60/82 (73.2%)
- 50 samples, which had significantly lower levels of human cfDNA than failed samples (p<0.0001). McfDNA
- 51 detection was significantly higher in Micro-SI (15/16 [94%]) compared to Clinical-SI samples (8/14 [57%],
- 52 p=0.03), and unexpectedly common in No-Suspected-SI samples (25/30 [83%]), similar to detection rate in
- 53 Micro-SI. We detected culture-concordant mcfDNA species in 13/16 Micro-SI samples (81%) and mcfDNA
- 54 levels tracked with SI outcome (resolution or persistence) under antibiotic therapy. McfDNA levels correlated
- 55 significantly with LRT bacterial burden (r=0.74, p=0.02) as well as plasma biomarkers of host response (white
- 56 blood cell count, IL-6, IL-8, and SPD, all p<0.05). Baseline mcfDNA levels were predictive of worse 90-day
- 57 survival (hazard ratio 1.30 [1.02-1.64] for each  $log_{10}$  mcfDNA, p=0.03).
- 58 <u>Interpretation</u>: High circulating levels of mcfDNA in a substantial proportion of patients with COVID-19 without
- 59 clinical suspicion for SI suggest that SIs may often remain undiagnosed. McfDNA-Seq, when clinically
- 60 available, can offer a non-invasive diagnostic tool for pathogen identification, with prognostic value on host
- 61 inflammatory response and clinical outcomes.
- 62 Key Words: COVID-19, microbial cell-free DNA sequencing, secondary infection, pneumonia, acute
- 63 respiratory failure

#### 64 Introduction:

65 Secondary bacterial or fungal infections complicate the course of up to 50% of hospitalized patients 66 with COVID-19 and contribute to worse clinical outcomes.<sup>1-3</sup> Diagnosis of secondary infections (SI) has 67 presented clinicians with major challenges during the pandemic. Readily available indicators of clinical infection such as fever, leukocytosis or consolidations on chest imaging cannot distinguish isolated SARS-CoV-2 68 69 infection from a secondary pneumonia by super-infecting organisms.<sup>4,5</sup> Blood cultures are obtained routinely when a SI is suspected in COVID-19, but their diagnostic yield is low, especially in the case of secondary 70 71 pneumonias, when direct lower respiratory tract (LRT) sampling is recommended.<sup>6</sup> LRT sampling for microbiologic studies can be challenging, such as in severely hypoxemic patients on non-invasive respiratory 72 73 support, and can have low diagnostic sensitivity, due to antecedent antibiotics or slow/fastidious organism 74 growth, as in the case of fungal pathogens.<sup>7</sup>

The challenges of SI diagnostic work-up and variable clinical practices have hindered acquisition of accurate SI incidence estimates in severely ill patients with COVID-19. With the prevailing diagnostic uncertainty, empiric antibiotics have been prescribed in 75-85% of hospitalized patients, often initiated due to clinical deterioration and then empirically continued, even in the absence of diagnostic evidence supporting an SI.<sup>8,9</sup> Overcoming the diagnostic challenges of SI with reliable, sensitive and non-invasive techniques could optimize diagnostic yield, enabling antibiotic targeting and stewardship.<sup>4</sup>

81 Metagenomic sequencing of plasma microbial cell-free DNA (mcfDNA) can offer a non-invasive, 82 sensitive diagnostic tool for SIs caused by DNA pathogens. Plasma metagenomics in sepsis provides rapid and actionable results, with 95% concordance with blood-cultured organisms, facilitating adjustments of 83 empiric antimicrobials to targeted therapy.<sup>10</sup> We have previously provided proof-of-concept evidence that 84 85 patients with COVID-19 with high levels of circulating mcfDNA of common respiratory pathogens were at risk of 86 worse clinical outcome.<sup>11</sup> Although the ability to comprehensively assess for SI-causal pathogens with non-87 invasive blood samples is appealing, feasibility and clinical validity data for mcfDNA sequencing in COVID-19 are needed. In this study, we report the analyses of a cohort of 42 hospitalized patients with severe COVID-19 88 89 who were comprehensively screened for SI pathogens with serial plasma mcfDNA sequencing.

- 90
- 91 Methods:

Clinical cohort enrollment and COVID-19 diagnosis: From April 2020 through September 2020, we 92 93 conducted an observational, prospective cohort study of hospitalized patients with acute hypoxemic respiratory failure and confirmed severe COVID-19 pneumonia as previously described.<sup>12,13</sup> The University of Pittsburgh 94 95 Institutional Review Board (IRB) approved the protocols and we obtained written or electronic informed 96 consent by all participants or their surrogates in accordance with the Declaration of Helsinki. We diagnosed 97 COVID-19 based on institutional clinical criteria (clinical symptoms, hypoxemia and abnormal chest radiographic findings) with confirmatory molecular testing (positive SARS-CoV-2 nasopharyngeal quantitative 98 polymerase chain reaction [gPCR]). 99

Biospecimen collection and experiments: We collected blood samples in EDTA tubes on enrollment (baseline - day 1) for centrifugation, separation and storage of plasma and additional blood constituents until conduct of experiments. We also collected repeat blood samples on days 5 and 10 post-enrollment from critically ill patients who remained hospitalized in the intensive care unit (ICU). We collected endotracheal aspirates (ETA) from mechanically-ventilated patients concurrently with blood sample acquisition.

105 We conducted plasma microbial cell-free DNA metagenomic sequencing (mcfDNA-Seq) with the Karius Test<sup>®</sup> [Karius Inc., Redwood City, CA] and classified the derived metagenomic sequences as human (hcfDNA) 106 vs. microbial (mcfDNA). Based on minimum sequencing coverage metric required for quality control, we 107 classified sequencing runs as "Pass", "Qualitatively Pass" or "Failed". All microbes were reported at species 108 level and included a quantitative measure of abundance expressed as DNA molecules per microliter (MPMs), 109 with the exception of the "Qualitative Pass" calls where the reported organism could not be quantified. We 110 classified microbes identified by mcfDNA-Seg into recognized respiratory pathogens vs. microbes of unclear 111 clinical importance.<sup>14</sup> For contextualization, we compared mcfDNA levels among subjects with COVID-19 with 112 our previously published dataset of mechanically ventilated patients with and without pneumonia.<sup>14</sup> 113

To profile the host response, we measured plasma levels of nine prognostic biomarkers (eight interleukin [IL]-6, IL-8, pentraxin-3, procalcitonin, receptor for advanced glycation end products [RAGE], angiopoietin-2 (Ang-2), suppression of tumorigenicity [ST]-2, and tumor necrosis factor receptor [TNFR]-1 with Luminex, and surfactant Protein D [SPD] with ELISA; R&D Systems, Minnesota). We measured plasma SARS-CoV-2 viral levels (vRNA) following RNA extraction and qPCR amplification with a sensitive in-house method.<sup>15</sup> From available ETA samples, we separately extracted genomic DNA and RNA and performed bacterial 16S

120 rRNA gene and SARS-CoV-2 RNA qPCR for assessment of bacterial and viral load in the LRT,

121 respectively.<sup>5,16</sup>

122 Diagnosis and classification of secondary infections:

We reviewed all available clinical, microbiologic and antimicrobial treatment data around the timing of baseline samples (+/- 3 days) for patients with COVID-19 to ascertain the presence/absence or clinical suspicion for SI. We classified subjects in three groups, assessed by two reviewers:

- a. Microbiologically-Confirmed Secondary Infection (**Micro-SI**), when typical pathogenic microbes were isolated on clinical biospecimen cultures (blood, LRT, urine or tissue) and the subject was receiving antimicrobials for the documented infection.
- b. Clinically-Diagnosed Secondary Infections (Clinical-SI), when empiric antimicrobials were administered
   without microbiologic SI confirmation.
- c. "No Clinical Suspicion for SI" (No-Suspected-SI), when microbiologic workup for SI was negative or
   not performed, and no empiric antimicrobials were prescribed.

We repeated classifications into the Micro-SI, Clinical-SI and No-Suspected-SI categories at the timing of follow-up samples (days 5 and 10 post-enrollment) from updated clinical and microbiologic data, when available. We quantified radiographic edema of baseline chest x-rays with the Radiographic Assessment of Lung Edema (RALE) score with the use of the *PulmAnnotator* software.<sup>17,18</sup>

137

### 138 Statistical analysis:

For "Pass" samples with zero microbial calls, we assigned a microbial MPM of "1" to allow for log<sub>10</sub>-139 transformations, and utilized log<sub>10</sub>-transformed values of plasma biomarkers and mcfDNA levels for analyses 140 due to non-normal data. We compared clinical variables, biomarker and cfDNA levels between different 141 categories (i.e. sequencing run success, SI clinical groups) and the historical non-COVID-19 cohort using non-142 parametric tests, Wilcoxon signed-rank and Fischer's exact tests. We examined for correlations between 143 biomarkers and cfDNA levels with the Pearson's method, adjusted for multiple comparisons with the 144 Benjamini-Hochberg method. We analyzed the impact of baseline mcfDNA levels on 90-day survival by 145 Kaplan-Meier curves stratified by total mcfDNA tertiles and by constructing Cox proportional age-adjusted 146 hazards models. We performed all analyses with the R software (R version 3.5.1). 147

148

# 149 **Results**:

150 Clinical cohort characteristics:

We included 42 patients (median age 65.1 years, 62% men), who contributed a total of 82 plasma samples for cfDNA sequencing (median of 2 samples per subject). From available baseline data, we classified subjects as Micro-SI (n=8), Clinical-SI (n=13) and No-Suspected-SI (n=21) (Table 1). We found lower rates of invasive mechanical ventilation (p = 0.05) and lower total white blood cell count (p=0.04) in Clinical-SI patients and no other significant clinical variable differences between SI groups. Plasma vRNA was notably lower in Micro-SI (p≤0.05). In biomarker comparisons, we found significant between-group differences in IL-8 and Ang-2 levels (lower in Clinical-SI).

158

# 159 Outputs of plasma metagenomic sequencing runs:

Based on the sequencing run success criteria of the 82 samples, we classified 52 (63%) as "Pass" 160 (successful), eight (10%) as "Qualitative Pass" and 22 samples (27%) as "Fail". "Pass" samples had 161 significantly lower levels of hcfDNA compared to "Qualitative Pass", or "Fail" samples (p<0.0001, e-Figure 1). 162 We also found that a successful sequencing run ("Pass") on a Day 1 sample for a given subject was 163 significantly associated with a "Pass" run on a Day 5 sample (Fisher's odds ratio 11.9, 95% confidence 164 interval-CI [1.00-703.8], p=0.04). From "Qualitative Pass" samples, we utilized only qualitative information 165 about identified microbial species, whereas we utilized quantitative mcfDNA data (expressed as MPMs) from 166 "Pass" samples only. 167

168

# 169 Plasma metagenomics results by SI category:

Among the 53 "Pass" samples across all time-points, Micro-SI diagnosis had more samples positive for mcfDNA (i.e. DNA reads from at least one microbial species reported, 15/16 [94%] samples) compared to Clinical-SI (8/14 [57%], p=0.03). Unexpectedly, a high proportion of No-Suspected-SI samples were positive for mcfDNA (25/30 [83%]), similar to Micro-SI samples. All eight "Qualitative Pass" samples, one Clinical-SI and seven No-Suspected-SI, were positive for mcfDNA, with 3/8 samples reporting ≥2 microbial species.

175 Among baseline "Pass" samples (n = 25), 18 (72%) were positive for mcfDNA, with a median (interguartile range - IQR) of 812.9 (151.3-2435.5) MPMs per sample, 59.1% of which corresponded to typical 176 177 pathogenic organisms. Stratified by SI categories, 4/5 (80.0%) Micro-SI, 3/8 (37.5%) Clinical-SI and 11/12 (91.6%) No-Suspected-SI samples were positive for mcfDNA, with a statistically significant higher proportion of 178 179 positive samples in No-Suspected-SI compared to Clinical-SI samples (Fisher's p=0.01). We found no significant differences in hcfDNA, total mcfDNA and pathogen mcfDNA MPMs between SI groups (Figure 1A-180C), although Micro-SI samples had numerically higher total and pathogen mcfDNA MPM levels (Table 1). 181 Among baseline "Pass" samples in Micro-SI subjects, plasma metagenomics reported mcfDNA from 182 the culprit organisms identified by cultures in 3/5 (60.0%) cases (E.coli in subject 4, Pseudomonas aeruginosa 183 in subject 3 and Proteus mirabilis in subject 6) (e-Figure 2, eTable 2). The two discordant Micro-SI samples 184 involved two probable ventilator-associated pneumonia (VAP) cases; subject 1 with negative mcfDNA-Seg 185 when LRT cultures taken three days prior to plasma sampling showed rare *E.coli* growth, and case subject 2 186 with light Methicillin-sensitive S. aureus growth in LRT cultures taken two days prior to plasma sampling was 187 deemed as culprit, but mcfDNA-Seg reported E. faecalis and E.coli mcfDNA. When considering all available 188 Micro-SI samples (five baseline and 11 follow-up samples), mcfDNA-Seq results were concordant with cultures 189 in 13/16 (81.3%) of comparisons. 190

Baseline samples from Clinical-SI subjects contained mcfDNA in 37.5 % of cases (3/8). Case 11 had high mcfDNA levels for plausible pathogens (*K. pneumoniae* and *P. aeruginosa*; Figure 1C, e-Figure 2, and eTable 2), which had not been detected by blood cultures (no LRT specimen cultures available). For the other two Clinical-SI subjects (15 and 21), reported mcfDNA belonged mostly to Human Herperviruses, which could represent viral re-activation in context of critical illness.<sup>19</sup>

Among No-Suspected-SI patients at baseline, 11/12 (91.6%) samples were positive for mcfDNA, with five samples showing >100 pathogen mcfDNA MPMs in the range of Micro-SI subjects (annotated species in Figure 1C, e-Figure 2). The remaining six subjects with mcfDNA revealed organisms of unclear clinical significance: Herpesvirus DNA in four subjects (27, 28, 38 and 42), and gram-positive bacteria often considered as skin contaminants in blood cultures (*Lactobacillus gasseri* and *S. epidermidis*) in three subjects (38, 41 and 42). Notably, 3/4 (75%) of the baseline "Qualitative Pass" samples for No-Suspected-SI subjects

202 (25, 30, 36) were also positive for pathogen mcfDNA, even though the absolute burden of mcfDNA MPMs

203 could not be reliably estimated.

204

### 205 Comparison of circulating cfDNA burden in COVID-19 vs. historic non-COVID samples:

206 Comparing against published data from our group for mechanically ventilated patients with 207 microbiologically confirmed pneumonia (n=26), clinically diagnosed pneumonia (n=41) and uninfected controls 208 (n=16, intubated for airway protection or due to cardiogenic pulmonary edema), we found markedly higher

209 levels of hcfDNA in subjects with COVID-19 compared to all non-COVID patient groups (e-Figure 3A, p<0.005</p>

210 for all comparisons). Patients without COVID with microbiologically confirmed pneumonia had higher mcfDNA

211 levels compared to No-Suspected-SI in patients with COVID-19, who in turn had markedly higher mcfDNA

levels compared to uninfected controls (e-Figure 3B-C, all p<0.05).

213

# 214 Trajectories of plasma cfDNA levels in subjects with COVID-19:

We updated SI classifications at the time of the follow-up sample acquisition and found that few subjects transitioned into a different SI diagnostic category (4/26 [15%] and 4/16 [25%] for days 5 and 10, respectively, e-Figure 4, 5). Micro-SI subjects had significantly higher total and pathogen mcfDNA levels

compared to No-Suspected-SI subjects at post-enrollment day 5 (p<0.05, e-Figure 5).

219 We examined subject-level trajectories in four cases with persistent culture-proven SI or persistent pathogen mcfDNA detection on available longitudinal samples (Figure 2). Subject 3 was diagnosed with 220 resistant Pseudomonas aeruginosa VAP with clinical and microbiologic relapse, demonstrating persistently 221 elevated Pseudomonas aeruginosa mcfDNA for >30 days on repeated sampling (Figure 2). For subject 4 222 223 McfDNA-Seq demonstrated a transition in detected bacterial species in follow-up samples corresponding to two different VAP episodes (by E. coli and Pseudomonas aeruginosa respectively). Subject 6 had unexplained, 224 persistent Proteus mirabilis mcfDNA detection following treatment of a urinary tract infection, but was found to 225 have a late parotid gland abscess that was drained and cultures grew Proteus mirabilis. Last, for subject 26 226 227 diagnosed as No-Suspected-SI (i.e. no empiric antimicrobials) who died on day 6 with multi-organ failure attributed to isolated SARS-CoV-2 infection, we found high pathogen mcfDNA levels, including Klebsiella 228 229 pneumoniae, raising concern for the possibility of an undetected and undertreated SI.

230

### 231 McfDNA is associated with plasma host-response biomarkers and LRT bacterial burden:

We next examined the relationship between mcfDNA-Seq results and clinical/laboratory parameters of 232 COVID-19 severity. We found no significant correlation between mcfDNA and SARS-CoV-2 viral load (plasma 233 and ETA vRNA), radiographic severity (quantified by RALE scores) or clinical severity by WHO ordinal scale. 234 235 However, there was a weak, significant correlation between hcfDNA and RALE scores (r=0.33, p=0.03). 236 We then examined for correlations between cfDNA levels and host-response biomarkers measured in plasma. Total and pathogen mcfDNA levels were significantly correlated with IL-6. IL-8 and SPD levels. 237 whereas hcfDNA levels were significantly correlated with IL-6, IL-8, pentraxin-3 and procalcitonin levels 238 following adjustment for multiple comparisons (Figure 3). Pathogen mcfDNA levels were significantly correlated 239 with 16S rRNA gene copies by gPCR in ETA specimens, a surrogate of LRT bacterial load (r=0.92, p=0.0004). 240241 Baseline mcfDNA levels are predictive of 90-day survival: 242 243 Baseline hcfDNA and total mcfDNA levels were not significantly associated with cumulative mortality at 90 days from ICU admission (Figure 4A-B). However, baseline total mcfDNA levels were significantly 244 associated with worse 90-day survival in a Cox proportional hazards model adjusted for age (hazard ratio for 245 log<sub>10</sub>-transformed mcfDNA 1.30, [1.02-1.64], p=0.03). Stratified by baseline total mcfDNA tertiles (high>1499, 246 247 middle 344-1499, low<344 MPMs), subjects in the high mcfDNA tertile had worse 90-day survival by Kaplan-Meier curve analysis compared to subjects in other tertiles (global log-rank p=0.02), whereas hcfDNA tertiles 248

were not predictive of 90-day survival (Figure 4C-D). In contrast to the significant prognostic information of baseline total mcfDNA levels, there were no 90-day survival differences between the clinical classification SI groups (log-rank p=0.62 for Micro-SI, Clinical-SI and No-Suspected-SI, data not shown). Stratified by 90-day survival, we found no significant differences in the longitudinal trajectories of total mcfDNA and hcfDNA levels between survivors and non-survivors (e-Figure 5A, B).

254

#### 255 **Discussion**:

In this exploratory study, we systematically evaluated 42 COVID-19 inpatients with culture-independent
 mcfDNA-Seq. We found no significant differences in mcfDNA levels by SI clinical categories at baseline,

although culture-confirmed cases of SI (Micro-SI) had higher mcfDNA levels on follow-up samples. The 258 259 mcfDNA species corresponded to clinically isolated pathogens in 81% of Micro-SI samples, and indicated potentially missed, super-infecting pathogens in up to 41% of subjects for whom there was no clinical suspicion 260for SI (No-Suspected-SI). Our molecular analyses revealed significant correlations of circulating mcfDNA levels 261 with LRT bacterial burden, suggestive of plausible secondary pneumonias, as well as with plasma host-262 response biomarkers. Subjects with the highest tertile of mcfDNA burden had significantly lower 90-day 263 264 survival independent of SI group. Longitudinal assessments revealed that mcfDNA levels can persist in SI without adequate source control such as the patient with parotitis or potentially with antibiotic resistant 265 pathogens such as the patient with resistant Pseudomonas VAP. Our results were also notable for an 266 unexpectedly high rate of failed mcfDNA-Seg runs due to high burden of circulating hcfDNA, which was much 267 higher than historic cases of non-COVID-19 pneumonia, perhaps due to significant human tissue damage in 268severely ill patients with COVID-19, including patients supported by extra-corporeal membrane oxygenation. 269 The higher likelihood of subsequent failed samples after initial failed samples suggests subject-specific 270271 influences on sequencing run outputs and results.

Our study highlights the challenge of clinically distinguishing cases with isolated SARS-CoV-2 infection 272from those complicated by SIs. The results of host-response biomarker analyses and mcfDNA-Seg did not 273 match the clinical SI diagnoses and clinically-directed microbiologic work-up. For example, procalcitonin levels 274 275 are often used as diagnostic biomarkers for bacterial infections, but have unclear diagnostic value for SIs in COVID-19.<sup>20,21</sup> We found similar procalcitonin levels among clinical SI groups, and importantly no significant 276 association with mcfDNA levels. The clinical validity of mcfDNA sequencing was further supported by the 277 significant correlations with LRT bacterial burden and systemic host-response biomarkers, as well as by the 278279 predictive value on 90-day survival. Our study suggests that noninvasive mcfDNA sequencing may offer insights into the presence of an SI and its impact on outcome. 280

281 Circulating mcfDNA was significantly associated with host immune response in COVID-19. McfDNA 282 species may reflect SI-causal pathogens (regardless of their viability in the bloodstream), but may also signify 283 lung barrier disruption in patients with acute lung injury from COVID-19, or even gut barrier disruption in 284 patients with circulatory shock and hypoperfusion.<sup>14</sup> Thus, positive mcfDNA calls should not be directly 285 interpreted as evidence of superinfecting pathogens, but interpreted within the context of a critical illness with

colonized mucosal surfaces by microbiota and impaired barrier function. The significant correlation between 286 hcfDNA levels and RALE scores suggests that lung injury may account, at least in part, for the systemic levels 287 of circulating hfcDNA. The significant correlations of mcfDNA with IL-6 and IL-8 levels highlighted the potential 288importance of mcfDNA in the inflammatory cascade of COVID-19, since mcfDNA can be recognized by Toll-289 like receptors and propagate systemic inflammatory responses, independent of the effects of SARS-CoV-2 on 290 innate immunity.<sup>22</sup> Additionally, the case of Herpesvirus DNA identification highlighted the prevalence of viral 291 re-activation in critical illness. Thus, any positive mcfDNA signal requires careful interpretation, as it may 292 293 represent superinfecting bacterial or fungal VAP pathogens, translocating commensal microbes, sample 294 collection skin/environmental contaminants or re-activated viral organisms.

Our study has several limitations. The sample size of 42 subjects limits the statistical power for some of 295 the analyses, yet it is to our knowledge the largest study to utilize plasma metagenomics in patients with 296 COVID-19, and we found significant associations with host inflammation and outcomes, consistent with our 297 hypotheses. Clinical samples for microbiologic workup were collected at the discretion of the treating clinicians, 298 thus some of the mcfDNA-culture comparisons are limited. Nonetheless, our clinical dataset is 299 and 300 representative of standard of care at a tertiary academic center. We systematically examined all patients for molecular evidence of possible SI using systematic evaluation with mcfDNA testing, regardless of clinician 301 impressions. It is possible that for certain No-Suspected-SI subjects, the mcfDNA reported may not represent 302 303 an active infection. Careful review of the mcfDNA-Seq output and integration with available evidence on organismal pathogenicity can help further inform interpretation of pathogen mcfDNA. Nonetheless, circulating 304 mcfDNA carries prognostic information underlined by the significant associations with systemic inflammation 305 and survival.<sup>11</sup> Our study was limited by an unexpected amount of failed mcfDNA-Seg analyses due to high 306 307 amounts of interfering hcfDNA, but this finding provided important insight into the high degree of human cellular damage in COVID-19. 308

Our study advances understanding of the pathobiologic and diagnostic importance of circulating mcfDNA in COVID-19 and demonstrates limitations in clinical assessment of SIs. McfDNA correlated with biomarkers of host immune response and LRT microbial burden. Additional characterization of host inflammatory response components and triggers in COVID-19 is essential in the era of immunomodulatory therapeutics. The noninvasive modality of quantifying mcfDNA load and accurately identifying microbial

- 314 species may offer a sensitive tool for SI detection, as well as further advance our understanding of the role of
- 315 translocating microbiota in critical illness. McfDNA sequencing may be particularly helpful in spontaneously
- 316 breathing patients on high flow nasal cannula or non-invasive mechanical ventilation, for whom access to LRT
- 317 specimens is challenging. Further prospective investigation for treatment guidance is necessary to
- 318 systematically evaluate the incidence of molecular evidence for SI and examine the impact of non-invasive
- 319 screening on patient outcomes.

# 320 References

- 3211.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19322in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062.
- Rouze A, Martin-Loeches I, Povoa P, et al. Relationship between SARS-CoV-2 infection and the
   incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort
   study. Intensive Care Med. 2021;47(2):188-198.
- 326 3. Maes M, Higginson E, Pereira-Dias J, et al. Ventilator-associated pneumonia in critically ill patients with 327 COVID-19. *Crit Care*. 2021;25(1):25.
- 3284.Pickens CO, Gao CA, Cuttica MJ, et al. Bacterial Superinfection Pneumonia in Patients Mechanically329Ventilated for COVID-19 Pneumonia. Am J Respir Crit Care Med. 2021;204(8):921-932.
- 3305.Kitsios GD, Morris A. Seek and Ye Shall Find: COVID-19 and Bacterial Superinfection. Am J Respir Crit331Care Med. 2021;204(8):875-877.
- Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among
   hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect.* 2020;26(10):1395-1399.
- 3357.Investigators NC. Bronchoscopy on intubated patients with COVID-19 is associated with low infectious336risk to operators. Annals of the American Thoracic Society. 2021;18(7):1243-1246.
- 3378.Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review338and meta-analysis. Clin Microbiol Infect. 2021;27(4):520-531.
- Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in
   patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK
   study: a multicentre, prospective cohort study. *The Lancet Microbe.* 2021;2(8):e354-e365.
- 34210.Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell-free DNA343sequencing test for infectious disease. Nat Microbiol. 2019;4(4):663-674.
- 34411.Kitsios GD, Bain W, Al-Yousif N, et al. Plasma microbial cell-free DNA load is associated with mortality in345patients with COVID-19. *Respir Res.* 2021;22(1):24.
- 12. Drohan CM, Nouraie SM, Bain W, et al. Biomarker-Based Classification of Patients With Acute
   Respiratory Failure Into Inflammatory Subphenotypes: A Single-Center Exploratory Study. *Crit Care Explor.* 2021;3(8):e0518.
- Bain W, Yang H, Shah FA, et al. COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome:
   Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical
   Outcomes. Ann Am Thorac Soc. 2021;18(7):1202-1210.
- 35214.Yang H, Haidar G, Al-Yousif NS, et al. Circulating microbial cell-free DNA is associated with353inflammatory host-responses in severe pneumonia. *Thorax.* 2021;76(12):1231-1235.
- 35415.Jacobs JL, Bain W, Naqvi A, et al. SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts355Clinical Outcomes. Clin Infect Dis. 2021.
- Jacobs J, Naqvi A, Shah F, et al. Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract
   SARS-CoV-2 infection in critically ill patients with COVID-19. *Journal of Infectious Diseases*. 2022;In
   press.
- 35917.Kotok D, Yang L, Evankovich JW, et al. The evolution of radiographic edema in ARDS and its association360with clinical outcomes: A prospective cohort study in adult patients. J Crit Care. 2020;56:222-228.
- Al-Yousif N, Komanduri S, Qurashi H, et al. Radiographic Lung Edema in Hospitalized Patients with
   COVID-19 Is Associated with Disease Severity and Clinical Outcomes. *B104. COVID ACROSS THE CARE CONTINUUM*: American Thoracic Society; 2022:A3554-A3554.
- 36419.Meyer A, Buetti N, Houhou-Fidouh N, et al. HSV-1 reactivation is associated with an increased risk of365mortality and pneumonia in critically ill COVID-19 patients. Crit Care. 2021;25(1):417.

- 36620.Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not367reflect bacterial co-infection. Ann Clin Biochem. 2021;58(5):520-527.
- Atallah NJ, Warren HM, Roberts MB, et al. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study. *PLoS One.* 2022;17(1):e0262342.
- 370 22. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of 371 sepsis-associated pathology and infectious diseases. *Frontiers in immunology*. 2013;4:387.

# **TABLE 1: Cohort characteristics by COVID-19 and SI category**

Variable	All patients	Micro-SI	Clinical-SI	No-Suspected-SI	P-value
N	42	8	13	21	
Male, n (%)	26 (61.9)	6 (75.0)	8 (61.5)	12 (57.1)	0.68
Age (median [IQR])	65.1 [58.4, 76.5]	61.6 [56.4, 65.6]	73.5 [61.6, 76.7]	64.7 [58.1, 76.8]	0.26
BMI (median [IQR])	32.3 [26.5, 39.1]	32.3 [28.6, 41.1]	33.5 [30.8, 36.4]	30.1 [26.2, 38.9]	0.58
Diabetes, n (%)	18 (42.9)	5 (62.5)	3 (25.0)	10 (47.6)	0.17
COPD, n (%)	10 (23.8)	2 (25.0)	3 (25.0)	5 (23.8)	0.99
Immunosuppression, n (%)	4 (9.5)	1 (12.5)	0 (0.0)	3 (14.3)	0.37
Invasive Mechanical Ventilation, n	27 (64.3)	7 ( 87.5)	5 ( 38.5)	15 ( 71.4)	0.05
(%)					
ECMO, n (%)	8 (19.5)	3 (37.5) 1 (7.7) 4 (1		4 (19.0)	0.24
WBC (median [IQR])	10.2 [6.7, 12.4]	13.3 [10.0, 14.2]	6.7 [5.9, 11.8]	10.6 [7.4, 11.7]	0.04
WHO ordinal scale at ICU admission	8.0 [7.2, 9.0]	7.0 [5.0, 9.0]	7.0 [6.0, 7.0]	6.0 [5.0, 6.0]	0.22
(median [IQR])					
RALE score (median [IQR])	24.0 [21.1, 31.2]	21.8 [20.6, 23.1]	22.2 [21.0, 32.6]	26.2 [23.0, 35.8]	0.10
SARS-CoV-2 RNA in Plasma (cps/mL,	867.0 [40.0, 5,742.5]	3.0 [3.0, 3.0]	1,795.5 [86.5,	2,491.0 [220.0, 5,445.0]	0.05
median [IQR])			6,840.0]		
SARS-CoV-2 RNA in ETA (cps/mL,	215,466.7 [2,718.8, 729,422.2]	29.0 [29.0, 2,804.8]	338,240.0	339,911.1 [33,351.1, 950,400.0]	0.18
median [IQR])			[17,920.0,		
			508,444.4]		
IL-6 pg/ml (median [IQR])	37.1 [15.7, 159.5]	128.0 [66.9, 188.4]	26.9 [14.7, 41.4]	36.0 [16.8, 165.7]	0.44
IL-8 pg/ml (median [IQR])	22.8 [14.7, 41.4]	29.1 [19.9, 52.4]	13.9 [7.1, 20.0]	29.9 [17.6, 53.6]	0.05
ST2 pg/ml (median [IQR])	190532.0 [95113.3, 268265.7]	190,174.0 [89,313.7,	206,023.5	185961.2 [97840.6, 253415.2]	0.79
		276,629.2]	[151,105.8,		
			270,770.7]		
TNFR1 pg/ml (median [IQR])	4539.0 [3500.3, 8877.2]	7,622.3 [4,678.7,	4,072.4 [3,179.9,	4498.0 [3390.3, 9493.9]	0.28
		11,256.5]	5,512.4]		
SPD pg/ml (median [IQR])	25.1 [14.0, 57.6]	40.0 [21.9, 83.8]	39.0 [27.0, 55.1]	20.5 [8.3, 29.7]	0.26
RAGE pg/ml (median [IQR])	4576.8 [2422.6, 9071.2]	2,519.2 [1,566.5,	2,689.6 [2,383.5,	5879.8 [3856.5, 9982.9]	0.17
		8,520.3]	8,455.6]		
Ang-2 pg/ml (median [IQR])	4354.0 [2484.3, 7375.3]	9,805.2 [5,706.4,	3,292.3 [2,098.3,	3,195.6 [2,422.8, 5,096.5]	0.01

		14,848.5]	7,299.0]		
Procalcitonin pg/ml (median [IQR])	461.0 [187.9, 1516.1]	403.8 [164.1, 798.8]	206.1 [147.6,	815.1 [272.2, 1767.8]	0.08
			454.8]		
Pentraxin-3 pg/ml (median [IQR])	7826.2 [3584.4, 16080.0]	6,908.7 [2,682.9,	6,827.5 [3,649.9,	13548.5 [3976.4, 20466.9]	0.14
		8,793.6]	11,186.3]		
Human cfDNA MPM (median [IQR])	563.5 [148.6, 1284.8]	750.6 [200.8, 1,299.4]	325.9 [109.1,	686.2 [148.7, 2253.5]	0.17
			563.7]		
Total microbial cfDNA MPM (median	812.9 [151.3, 2435.5]	1,614.9 [794.8,	1.0 [1.0, 818.1]	1026.6 [457.7, 2464.9]	0.17
[IQR])		1,7812.8]			
Bacterial cfDNA MPM (median [IQR])	600.4 [1.0, 2906.1]	9,349.2 [559.7,	1.0 [1.0, 86.0]	822.9 [117.9, 1956.0]	0.07
		28,503.5]			
Fungal cfDNA MPM (median [IQR])	1.0 [1.0, 1.0]	158.8 [1.0, 388.7]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	<0.01
Respiratory pathogen cfDNA MPM	1.0 [1.0, 1,480.8]	9,349.2 [559.7,	1.0 [1.0, 13.5]	118.0 [1.0, 1480.8]	0.06
(median [IQR])		28,503.5]			

274

\*COVID-19 diagnosis made by positive nasopharyngeal (NP) qPCR test for SARS-CoV-2 in 42/43 subjects, and for one subject with negative NP

375 qPCR test by positive anti-spike protein antibodies (patient enrolled in April 2020, prior to initiation of vaccination programs). P-values significant

below threshold of 0.05 are shown in bold. Abbreviations: Microbiologically-Diagnosed Secondary Infection (Micro-SI); Clinically-Diagnosed

377 Secondary Infections (Clinical-SI); No Clinical Suspicion for SI (No-Suspected-SI); chronic obstructive pulmonary disease (COPD); extracorporeal

378 membrane oxygenation (ECMO); Radiographic Assessment of Lung Edema score (RALE score); receptor for advanced glycation end products

379 (RAGE); suppression of tumorigenicity (ST-2); tumour necrosis factor receptor (TNFR-1); Surfactant Protein D (SPD); molecules per microliter

380 (MPMs).







- significant differences in human (A) or microbial cell-free DNA levels (B-C). Subjects classified as
- 386 Microbiologically-Confirmed Secondary Infection (Micro-SI) had numerically higher but statistically non-
- 387 significant different levels of total and pathogen microbial cell-free DNA (mcfDNA) compared to subjects
- 388 classified as Clinically-Diagnosed Secondary Infections (Clinical-SI) or those with no Clinical Suspicion for SI
- 389 (No-Suspected-SI). Pairwise comparisons were conducted with Wilcoxon test. In panel C, the most abundant
- microbial species in each of the positive samples for pathogen mcfDNA are shown.

# 391 Figure 2:



392

393 Figure 2: Comparison of plasma mcfDNA sequencing with microbiologic/clinical diagnoses across the timeline of four subjects with serial sampling. Species-specific microbial MPMs (y-axis) are shown across sequential 394 395 sampling days from enrollment, (x-axis). Petri dish graphics along the x-axis denote the timing and results of 396 clinically obtained microbiological testing. Subject 3 (A) was an immunocompetent patient with a persistent 397 culture-confirmed Pseudomonas VAP that persisted through the antimicrobials, with timing and therapy noted 398 above. Subject 3 had persistently elevated Pseudomonas mcfDNA levels throughout the extended infection 399 course, which ultimately correlated with clinical improvement (A). Subject 4 (B) had sequential VAPs with 400 changing pathogens detected on invasive respiratory cultures, E. coli followed by Pseudomonas, which was 401 concordantly reported on noninvasive mcfDNA sampling. Subject 6 (C) was a patient with diabetes who was initially found to have a resistant Proteus urinary infection, and a subsequent persistent septic clinical picture. 402 403 later found to have a polymicrobial, including Proteus, parotid gland abscess. Proteus mcfDNA levels remained 404 elevated in Subject 6 during initial antimicrobial therapy for urinary infection, suggesting the persistent source of infection. Subject 26 (D) was clinically determined No-Suspicion-for-SI, but had a deteriorating clinical 405 406 course, without cultures obtained for 5 days or empiric antimicrobials, and ultimately died of shock and multisystem organ failure. Noninvasive testing revealed persistent levels of Klebsiella pneumonia mcfDNA 407 levels, which suggests an undiagnosed SI may have contributed to the clinical course. 408409 Figure 3:



410

Figure 3: Plasma microbial cell-free DNA levels were significantly correlated with lower respiratory tract 411 bacterial load and plasma host response biomarkers. Correlogram demonstrating comparisons of host nine 412 response biomarkers (green dashed box), number of 16S rRNA gene copies by gPCR in Endotracheal 413 414 Aspirates (ETA, surrogate for lower respiratory tract bacterial load), number of SARS-COV-2 RNA copies in ETA and plasma samples by gPCR, and mcfDNA-Seg output (hcfDNA, total mcfDNA and pathogen mcfDNA -415 purple dashed box). Significant correlations with the Pearson's method and following adjustment for multiple 416 comparisons by the Benjamini-Hochberg method are shown, with direction and strength of correlation depicted 417 by the color scale on the right panel. 418

### 420 Figure 4:



421

Figure 4: Highest microbial cell-free DNA levels at baseline were significantly associated with worse 90-day survival. 90-day non-survivors had numerically higher (but statistically non-significant) plasma hcfDNA (A) and mcfDNA (C) levels. HcfDNA levels were not significantly associated with 90-day survival by Kaplan-Meier analysis (B). Patients with the highest tertile of mcfDNA (>1499 Molecules per Microliter) had significantly worse survival compared to patients in the other two mcfDNA tertiles (D). In a Cox proportional hazards model adjusted for age, mcfDNA levels were significantly associated with increased hazards of death (D, adjusted hazard ratio for log<sub>10</sub>-transformed mcfDNA 1.30, 95% confidence interval 1.02-1.64, p=0.03).

430 SUPPLEMENT:
431 e-Table 1: Baseline characteristics by sequencing run success.

Variable	Pass	Pass Qualitatively	Fail	P-value
N	25	5	12	
Male, n (%)	20 (64.5)	1 (20.0)	8 (61.5)	0.12
Age (median [IQR])	68.7 [60.2, 76.8]	78.4 [63.1, 86.8]	58.5 [57.2, 64.7]	0.04
BMI (median [IQR])	31.6 [26.4, 34.0]	30.1 [26.8, 36.4]	39.6 [28.7, 42.4]	0.35
Diabetes, n (%)	11 ( 44.0)	3 ( 60.0)	4 ( 33.3)	0.59
COPD, n (%)	9 ( 36.0)	1 ( 20.0)	0 ( 0.0)	0.05
Immunosuppression, n (%)	2 ( 8.0)	1 ( 20.0)	1 ( 8.3)	0.7
Invasive Mechanical Ventilation, n (%)	14 ( 56.0)	4 ( 80.0)	9 ( 75.0)	0.39
ECMO, n (%)	3 ( 12.0)	1 ( 20.0)	4 ( 33.3)	0.3
WBC (median [IQR])	9.4 [6.3, 11.8]	11.1 [11.1, 11.5]	10.2 [7.4, 13.7]	0.46
WHO ordinal scale at ICU admission (median [IQR])	5.0 [5.0, 6.0]	5.5 [5.0, 6.5]	7.0 [6.0, 8.5]	0.01
RALE score (median [IQR])	22.5 [21.0, 28.0]	23.0 [22.8, 24.0]	27.5 [20.6, 35.8]	0.56
SARS-CoV-2 RNA in Plasma (cps/mL, median [IQR])	196.5 [3.0, 3349.0]	6352.0 [3286.0, 26029.3]	2491.0 [335.0, 6874.5]	0.3
IL6 pg/ml (median [IQR])	33.9 [16.9, 124.9]	165.7 [89.7, 1109.9]	51.1 [15.7, 221.3]	0.19
IL8 pg/ml (median [IQR])	22.2 [13.9, 33.6]	35.9 [29.9, 181.2]	17.6 [15.1, 62.3]	0.29
ST2 pg/ml (median [IQR])	142138.6 [78170.4, 198277.7]	253415.2 [218252.9, 578677.0]	287500.3 [216718.3, 328329.0]	<0.01
TNFR1 pg/ml (median [IQR])	4186.0 [3555.3, 7971.9]	9493.9 [6465.9, 12598.6]	4919.9 [3417.1, 6956.2]	0.44
SPD pg/ml (median [IQR])	24.3 [10.0, 43.0]	80.5 [20.8, 141.9]	26.0 [13.2, 53.1]	0.46
RAGE pg/ml (median [IQR])	4245.9 [2419.5, 9023.2]	4518.6 [2410.7, 9982.9]	5518.4 [2884.1, 7936.1]	0.97
Ang-2 pg/ml (median [IQR])	3905.8 [1935.6, 7130.4]	4505.1 [3942.7, 8903.3]	4543.4 [2886.8, 10443.9]	0.5
Procalcitonin pg/ml (median [IQR])	280.0 [167.0, 558.5]	3630.8 [1767.8, 4556.7]	580.8 [240.5, 1478.0]	0.01
Pentraxin-3 pg/ml (median [IQR])	6085.9 [2937.8, 13127.0]	19508.6 [6766.4, 32196.3]	12979.7 [7122.9, 18778.3]	0.1
Human cfDNA MPM (median [IQR])	200.3 [91.3, 424.2]	722.2 [686.2, 1299.7]	1343.1 [949.5, 3731.9]	<0.01

	Total microbial cfDNA MPM (median [IQR])	794.8 [1.0, 1863.1]	1480.8 [818.1, 21805.9]	NA	0.14
	Bacterial cfDNA MPM (median [IQR])	252.3 [1.0, 1343.9]	1480.8 [537.1, 21805.9]	42735.5 [42735.5, 42735.5]	0.13
	Fungal cfDNA MPM (median [IQR])	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	0.67
	Respiratory pathogen cfDNA MPM (median [IQR])	1.0 [1.0, 1015.8]	1480.8 [1.0, 21805.9]	42735.5 [42735.5, 42735.5]	0.12
432	P-values significant below threshold of 0.05 are s	hown in bold. Abbreviations	Microbiologically-Diagnosed S	Secondary Infection (Micro-SI);	
433	Clinically-Diagnosed secondary infections (Clinic	al-SI); No Clinical Suspicion	for SI (No-Suspected-SI); chroi	nic obstructive pulmonary diseas	se

434 (COPD); extracorporeal membrane oxygenation (ECMO); Radiographic Assessment of Lung Edema score (RALE score); receptor for advanced

435 glycation end products (RAGE); suppression of tumorigenicity (ST-2); tumour necrosis factor receptor (TNFR-1); Surfactant Protein D (SPD);

436 molecules per microliter (MPMs).





438

e-Figure 1: Successful plasma metagenomic sequencing runs had significantly lower levels of human cell-free 439 DNA compared to unsuccessful runs. We classified the derived metagenomic sequences as human (hcfDNA) 440 441 vs. microbial (mcfDNA), expressed as molecules per microliter (MPMs). Based on meeting minimum 442 sequencing coverage metric required for quality control, we classified sequencing runs as successful ("Pass"). "Qualitatively Pass" or "Failed". Baseline "Pass" samples had significantly lower hcfDNA compared to 443 "Qualitatively Pass" or "Failed" samples (Wilcoxon test pairs p<0.001, panel A). We also found that among 444 subjects with both Day 1 and Day 5 samples, those samples that failed on both time points per subject (i.e. "0" 445 446 sequencing success in panel B) had significantly higher hcfDNA levels compared to "Pass" samples on both days (Wilcoxon p-value < 0.001). 447

- 448
- 449
- 450
- 451

# 452 e-Figure 2:



**McfDNA results by Subject** 

453

e-Figure 2: Significantly higher proportion of positive samples with mcfDNA species calls in No-Suspected-SI

455 compared to Clinical-SI samples. We display samples grouped by SI classification and sample identifier,

456 showing the species and respective MPMs called by mcfDNA-Seq. Standardized bars indicate failed samples,

samples with no species called, and those with qualitative pass, yielding species each denoted with

458 standardized bar. Infrequently called species were combined for visual simplicity.

459

460 e-Figure 3:



461

e-Figure 3: Subjects with COVID-19 have much higher levels of human cell-free DNA compared to non-COVID
 subjects with and without pneumonia. To contextualize the circulating cfDNA load in our COVID-19 cohort, we
 compared hcfDNA, total mcfDNA and pathogen mcfDNA MPMs between the COVID-19 SI categories against

- 465 available published data from our group for mechanically ventilated patients with microbiologically-confirmed
- 466 pneumonia (n=26, MCP), clinically-diagnosed pneumonia (n=41, CDP) and uninfected controls (n=16,
- 467 intubated for airway protection or due to cardiogenic pulmonary edema). We found markedly higher levels of
- 468 hcfDNA in subjects with COVID-19 compared to all non-COVID patient groups (p-values shown for the No-
- 469 Suspected-SI only for parsimony). Non-COVID patients with microbiologically-confirmed pneumonia had higher
- 470 mcfDNA levels compared to patients with COVID-19 with No-Suspected-SI, who in turn had markedly higher
- 471 mcfDNA levels compared to uninfected controls.
- 472
- 473

474 e-Figure 4:

475



476 e-Figure 4: Longitudinal subject, mcfDNA and human cfDNA changes across SI classification. This Sankey plot

shows the subjects who transitioned between SI categories throughout the study from days 1, to 5, and 10 (A).

- 478 Height of bars represents number of subjects. Attrition occurred throughout the study leading to decreased
- 479 height of day 5 and 10 nodes. HcfDNA was not significantly different among SI groups across the study period
- 480 (B). Total mcfDNA was not significantly different among SI categories on enrollment (C). Micro-SI subjects had
- significantly higher total and pathogen mcfDNA versus No-Suspected-SI subjects at Day 5 (C, D).
- 482
- 483 e-Figure 5:





e-Figure 5: Human and total mcfDNA trajectories among survivors and non-survivors. Trajectories of human

486 cfDNA and total mcfDNA were not significantly different across the study period in survivors and non-survivors

487 (A, B).

- 488
- 489
- 490
- 491

492 e-Table 2: Subject cfDNA and culture results

ID	Day	SI group	cfDNA sequencing run	hcfDNA MPMs	McfDNA (Organism, MPMs)	Clinical microbiology results [Sample Type (Time from research sample): Results]	Synthesis of mcfDNA with clinical microbiology
1	1	Micro-SI	Pass	238.8	No Organism Reported, 0	- <u>Blood (</u> Day -3): NG - <u>BAL</u> (Day -3): GS: Many WBCs; Moderate GNRs; Cx: Rare <i>Escherichia coli</i> , Light NRF	- Discordant
	5	Micro-SI	Pass	457.4	Escherichia coli, 4208 Bacteroides vulgatus, 255		<ul> <li>Concordant</li> <li>Microbe of unclear clinical significance</li> </ul>
2	1	Micro-SI	Pass	36.8	Candida tropicalis, 481 Enterococcus faecalis, 174 Escherichia coli, 140	- <u>BAL</u> (Day -2): GS: Many WBCs, Few GPC; Cx: Light MSSA, NRF, Yeast	- Discordant
-	5	Micro-SI	Pass	49.0	Human herpesvirus 1, 449 Candida tropicalis, 75	<u>- CSF (D</u> ay -1): Cx: NG, PCR: HSV ND; Ag: Cryptococcal ND	<ul> <li>Discordant</li> <li>Microbe of unclear clinical significance</li> </ul>
-	10	No-Suspected-SI	Pass	24.0	No Organism Reported, 0	<u>- Blood</u> (Day -2): NG	- Concordant
3	1	Micro-SI	Pass	86.5	Pseudomonas aeruginosa, 1298 Candida parapsilosis, 317	<u>- Sputum</u> (Day -2): GS: Few WBCs, Moderate GNR; Cx: Moderate <i>Pseudomonas</i> <i>aeruginosa</i> , Rare NRF	- Concordant
	5	Micro-SI	Pass	132.5	Pseudomonas aeruginosa, 11148		- Concordant
	10	Micro-SI	Pass	155.6	Pseudomonas aeruginosa, 11455 Candida parapsilosis, 121	<u>- Sputum</u> (Day -2): GS: Moderate WBCs, Few GNR; Cx: Heavy <i>Pseudomonas</i> <i>aeruginosa</i> , Rare NRF <u>- Urine</u> (Day 0): Cx: NG	- Concordant, - Microbe of unclear clinical significance
	27	Micro-SI	Pass	332.6	Pseudomonas aeruginosa, 86832		<ul> <li>Culture not available</li> <li> concordant with prior infection</li> </ul>
	31	Micro-SI	Pass	47.7	Pseudomonas aeruginosa, 2763	- <u>Sputum (</u> Day -1): GS: Many WBCs, Few GNR Cx: Moderate <i>Pseudomonas</i> <i>aeruginosa</i> , Light NRF - <u>Urine (</u> Day -1): Cx: NG - <u>Stool</u> (Day +1): PCR: <i>C. difficile</i> ND	- Concordant

4	1	Micro-SI	Pass	1284.8	Escherichia coli, 17400 Candida tropicalis, 413	<u>- Blood</u> (Day -2): Staphylococcus epidermidis <u>- BAL</u> (Day -1): GS: Many WBCs, Rare GPCP Cx: Staphylococcus aureus (>100,000 cfu/mL), Escherichia coli (600 cfu/mL) <u>- Blood</u> (Day 0): NG	<ul> <li>Concordant,</li> <li>Microbe of unclear clinical significance</li> </ul>
	5	Micro-SI	Pass	773.2	Escherichia coli, 7388 Candida tropicalis, 841 Prevotella bivia, 278	<u>- Pleural Fluid (</u> Day +2): GS: Few WBCs, Cx: NG	<ul> <li>Concordant,</li> <li>Microbe of unclear clinical significance</li> </ul>
	11	Micro-SI	Pass	586.6	Escherichia coli, 228 Prevotella bivia, 96	<u>- Blood (</u> Day 0): Staphylococcus capitis	<ul> <li>Culture not available</li> <li> concordant with prior infection</li> <li>Microbe of unclear clinical significance</li> </ul>
	27	Micro-SI	Pass	86.0	Pseudomonas aeruginosa, 1101 Escherichia coli, 381 Human herpesvirus 1, 95 Burkholderia cepacia complex, 58	<u>- BAL</u> (Day 0): GS: Many WBCs, Many GNRs Cx: Heavy <i>Pseudomonas</i> <i>aeruginosa</i> <u>- Stool (Day 0): PCR:</u> C. difficile ND <u>- Blood:</u> (Day +1): NG	<ul> <li>Concordant,</li> <li>Microbe of unclear clinical significance</li> </ul>
5	1	Micro-SI	Fail	887.9	NA	<u>- BAL</u> (Day +2): GS: Many WBCs, Few GNR, Rare GPCP, Rare GPCCH, Cx: <i>Klebsiella aerogenes</i> (>100,000 cfu/mL), MSSA (52,000 cfu/mL)	- Comparison not possible
	5	Micro-SI	Fail	4306.1	NA	<u>- Blood (</u> Day -2): Fungitell: ND <u>- Stool</u> (Day +2): PCR: <i>C. difficile</i> Detected	- Comparison not possible
	10	Micro-SI	Fail	6076.6	NA	- ETA (Day -1): GS: Few WBCs, Cx: Light Klebsiella aerogenes, Rare MSSA, Rare NRF - Blood (Day -1): NG - BAL (Day 0): GS: Many WBCs, Cx: Klebsiella aerogenes (60,000 cfu/mL), Yeast	- Comparison not possible
6	1	Micro-SI	Pass	613.3	Proteus mirabilis, 32205	<u>- Blood (</u> Day +1): Staphylococcus epidermidis <u>- Urine (</u> Day +1): Cx:	- Concordant

						Proteus mirabilis (80,000 Col/mL), Yeast	
	5	Micro-SI	Pass	880.7	Proteus mirabilis, 409005 Human herpesvirus 4, 291	- Parotid gland drainage (Day +5): GS: No WBCs or organisms; Cx: Light MRSA, Rare Proteus mirabilis, Light Corynebacterium tuberculostearicum, Rare Corynebacterium striatum	- Concordant, - Microbe of unclear clinical significance
7	1	Micro-SI	Fail	1343.1	NA	<u>- BAL (</u> Day 0): GS: Moderate WBCs, Cx: NRF	<ul> <li>Comparison not possible</li> </ul>
	5	Clinical-SI	Pass	61.6	Candida tropicalis, 544	<u>- BAL (</u> Day -1): GS: No WBCs, Cx: Rare NRF	- Microbe of unclear clinical significance
	10	Clinical-SI	Pass	177.8	Candida tropicalis, 2171 Human herpesvirus 1, 1013	<u>- BAL (</u> Day +2): GS: No WBCs, Cx: Yeast	- Microbe of unclear clinical significance
8	1	Micro-SI	Fail	4274.9	NA	<ul> <li><u>Blood (Day +1): NG</u></li> <li><u>Urine (Day +1): Cx:</u> multiple organisms, likely contaminated</li> <li><u>Sputum (Day +1):</u> GS: Moderate WBCs, Cx: Rare NRF</li> </ul>	- Comparison not possible
9	1	Clinical-SI	Fail	1213.0	NA	<u>- BAL (</u> Day +2): GS: Many WBCs, Moderate GPCP, Moderate GPCCH; Cx: NRF	- Concordant
	5	Clinical-SI	Fail	1150.3	NA	- <u>BAL (</u> Day -2): GS: Many WBCs, Moderate GPCP, Moderate GPCCH, Cx: NRF <u>- Blood (</u> Day 0): NG	- Concordant
	10	Clinical-SI	Pass		Candida tropicalis, 112	<u>- Blood (</u> Day +1): NG	<ul> <li>Microbe of unclear clinical significance</li> </ul>
10	1	Clinical-SI	Pass	38.8	No Organism Reported, 0	- <u>Blood (</u> Day -2): NG - <u>Sputum (</u> Day +1): GS: Rare WBCs, Cx: NG	- Concordant
	5	No-Suspected-SI	Pass	592.5	No Organism Reported, 0		<ul> <li>Comparison not possible</li> </ul>
	10	No-Suspected-SI	Pass	342.6	Human herpesvirus 1, 110		- Microbe of unclear clinical significance
11	1	Clinical-SI	Pass	349.6	Klebsiella pneumoniae, 24841 Pseudomonas aeruginosa, 12119	<u>-Blood (</u> Day +2): NG	<ul> <li>Plausible pathogen identified</li> <li>Microbe of unclear clinical significance</li> </ul>

					Pediococcus acidilactici, 2800 Human herpesvirus 4, 574		
	5	Clinical-SI	Pass	690.5	Klebsiella pneumoniae, 4073 Enterococcus faecalis, 7331 Pseudomonas aeruginosa, 5413	<u>- Stool (</u> Day 0): PCR: <i>C. difficile</i> ND	- Plausible pathogen identified
12	1	Clinical-SI	Fail	551.7	NA	<u>- Stool (</u> Day -1): PCR: <i>C. difficile</i> ND	<ul> <li>Comparison not possible</li> </ul>
_	5	Clinical-SI	Pass	82.9	No Organism Reported, 0		<ul> <li>Comparison not possible</li> </ul>
	10	No-Suspected-SI	Pass	65.3	Escherichia coli, 763		<ul> <li>Plausible pathogen identified</li> </ul>
-	67	Micro-SI	Fail	9803.8	NA	<u>- BAL (</u> Day -7): GS: Few WBCs, Few GPCPCs, Cx: <i>Klebsiella</i> pneumonia, NRF	- Comparison not possible
13	1	Clinical-SI	Fail	11870.3	NA	- Urine (Day -2): Cx: NG (1,000 - 10,000 col/ml mixed growth of 3 or more organisms) - <u>Blood</u> (Day -1): NG - <u>Blood</u> (Day +2): NG - <u>Sputum</u> (Day +2): GS: Few WBCs, Cx: Light NRF	- Comparison not possible
	5	Clinical-SI	Fail	12444.5	NA	<u>- Blood</u> (Day -2): NG <u>- Sputum (D</u> ay -2): GS: Few WBCs, Cx: Light NRF <u>- Blood</u> (Day 0): NG <u>- Sputum</u> (Day 0): GS: Few WBCs, Cx: Rare NRF	- Comparison not possible
	10	Clinical-SI	Fail	11195.5	NA	<u>- Blood</u> (Day -1): NG	<ul> <li>Comparison not possible</li> </ul>
14	1	Clinical-SI	Pass	119.8	No Organism Reported, 0		- Comparison not
-	5	No-Suspected-SI	Pass	42.6	No Organism Reported 0		- Comparison not
15	1	Clinical-SI	Pass	200.3	Human herpesvirus 1, 2435 Streptococcus thermophilus, 128 Pantoea atis, 63	- Blind BAL (Day -2): GS: Few WBCs, Cx: 4200 cfu/mL, GNR No ID or sensitivity performed, Yeast	- Microbe of unclear clinical significance
16	1	Clinical-SI	Pass	319.9	No Organism Reported, 0	- <u>Blood</u> (Day 0): NG - <u>RCx (</u> Day +2): Cx: NRF	- Concordant
	5	Clinical-SI					<ul> <li>Comparison not possible</li> </ul>
17	1	Clinical-SI	Pass	30.8	No Organism	<u>- Blood</u> (Day -2): NG	- Concordant

					Reported, 0	<u>- Urine (</u> Day -1): Cx: NG	
18	1	Clinical-SI	Fail		NA		<ul> <li>Comparison not possible</li> </ul>
19	1	Clinical-SI	Pass	332.0	No Organism Reported, 0		<ul> <li>Comparison not possible</li> </ul>
-	5	Clinical-SI				<u>- RCx (</u> Day 0): Cx: Yeast	- Comparison not possible
	10	No-Suspected-SI				<u>- Blood</u> (Day -2): NG <u>- Urine (</u> Day -2): Cx: NG <u>- RCx (</u> Day -2): Cx: NRF	- Comparison not possible
						<u>- RCx</u> (Day +1): Cx: Yeast	
20	1	Clinical-SI	Pass Qualitatively	599.7	Human herpesvirus 4		- Microbe of unclear clinical significance
	5	Clinical-SI				<u>- RCx (</u> Day 0): Cx: NRF	<ul> <li>Comparison not possible</li> </ul>
	10	Clinical-SI					<ul> <li>Comparison not possible</li> </ul>
21	1	Clinical-SI	Pass	77.0	Human herpesvirus 4, 388 Bacteroides ovatus, 51	<u>- RCx (</u> Day 0): Cx: NRF	- Microbe of unclear clinical significance
22	1	No-Suspected-SI	Fail	2836.1	NA	<u>- Blood</u> (Day -2): NG <u>- Urine (</u> Day -2): Cx: NG	- Comparison not possible
23	1	No-Suspected-SI	Pass	133.6	Raoultella ornithinolytica, 1481		<ul> <li>Microbe of unclear clinical significance</li> </ul>
	5	No-Suspected-SI	Pass	47.6	Candida tropicalis, 89	<u>- Blood</u> (Day -1): NG	<ul> <li>Microbe of unclear clinical significance</li> </ul>
24	1	No-Suspected-SI	Pass	563.5	No Organism Reported, 0	<u>- Blood</u> (Day -2): NG	- Concordant
25	1	No-Suspected-SI	Pass Qualitatively	1299.7	Pseudomonas aeruginosa, Streptococcus mitis, Klebsiella variicola, Staphylococcus aureus,	<u>- Blood</u> (Day -2): NG	- Plausible pathogen identified
26	1	No-Suspected-SI	Pass	424.2	Klebsiella pneumoniae, 1673 Haemophilus parahaemolyticus, 1132 Haemophilus influenzae, 1022 Escherichia coli, 587 Enterococcus faecalis, 226		- Plausible pathogen identified
	5	No-Suspected-SI	Pass Qualitatively	4711.9	Human herpesvirus 4, Klebsiella pneumoniae,	<u>- Blood</u> (Day -1): NG	<ul> <li>Plausible pathogen identified</li> <li>Microbe of unclear clinical significance</li> </ul>

27	1	No-Suspected-SI	Pass	1229.0	Human herpesvirus 4, 220		<ul> <li>Microbe of unclear clinical significance</li> </ul>
_	5	No-Suspected-SI	Pass	345.4	Human herpesvirus 4, 619 Staphylococcus epidermidis, 200 Scardovia wiggsiae, 232		- Microbe of unclear clinical significance
	10	No-Suspected-SI	Pass	386.5	<i>Human herpesvirus</i> <i>4</i> , 164		<ul> <li>Microbe of unclear clinical significance</li> </ul>
28	1	No-Suspected-SI	Pass	2253.5	Human herpesvirus 4, 1863	<u>- Blood</u> (Day -3): NG <u>- Urine (</u> Day -2): Cx: NG	- Microbe of unclear clinical significance
29	1	No-Suspected-SI	Pass	373.1	Streptococcus parasanguinis, 505 Actinomyces odontolyticus, 270 Streptococcus gordonii, 205 Streptococcus sanguinis, 147 Rothia mucilaginosa, 88		<ul> <li>Plausible pathogen identified</li> <li>Microbe of unclear clinical significance</li> </ul>
30	5	No-Suspected-SI	Pass Qualitatively	24326.7	Corynebacterium striatum, Pseudomonas aeruginosa, Human herpesvirus 4,	- Bronchial Wash (Day -1): GS: Many WBCs, Many GNR, Many GPR, Cx: Heavy <i>Pseudomonas</i> <i>aeruginosa</i> , Heavy NRF	<ul> <li>Plausible pathogen identified</li> <li>Microbe of unclear clinical significance</li> </ul>
31	1	No-Suspected-SI	Pass	91.3	Klebsiella pneumoniae, 554 Staphylococcus aureus, 228 Haemophilus influenzae, 57		- Plausible pathogen identified
32	1	No-Suspected-SI	Pass	81.8	Actinomyces graevenitzii, 123 Helicobacter pylori, 121 Rothia mucilaginosa, 120 Streptococcus parasanguinis, 112 Streptococcus salivarius, 104 Streptococcus gordonii, 84	<u>- Blood</u> (Day -1): NG	<ul> <li>Plausible pathogen identified</li> <li>Microbe of unclear clinical significance</li> </ul>
33	1	No-Suspected-SI	Fail	1011.1	NA	<u>- BAL (</u> Day 0): GS: Moderate WBCs, Few GPCP, Cx: NRF	- Comparison not possible
_	6	No-Suspected-SI	Pass Qualitatively	973.8	Candida tropicalis	·	<ul> <li>Microbe of unclear clinical significance</li> </ul>
	10	No-Suspected-SI	Pass Qualitatively	1546.6	Candida tropicalis	<u>- BAL (</u> Day -1): GS: Few WBCs, Cx: Yeast , NRF	- Microbe of unclear clinical significance

						<u>- Blood</u> (Day 0): NG	
34	1	No-Suspected-SI	Fail	15218.0	NA	<u>- Blood</u> (Day -2): NG	<ul> <li>Comparison not possible</li> </ul>
	5	No-Suspected-SI	Fail	14729.6	NA		<ul> <li>Comparison not possible</li> </ul>
	10	No-Suspected-SI	Fail	3913.3	NA	- Blood (Day -1): NG - Sputum (Day -1): GS: Moderate GPCP, Few WBCs, Few Yeast, Few GPR, Cx: Heavy NRF	- Comparison not possible
35	1	No-Suspected-SI	Fail	591.5	NA		<ul> <li>Comparison not possible</li> </ul>
	5	Clinical-SI	Fail	632.2	NA	<u>- ETA (</u> Day -1): GS: Few WBCs, Rare GPCP, Moderate NRF <u>- ETA (</u> Day +2): GS: Few GPCP, Few GPR, Few GNR, Few WBCs, Cx: Moderate NRF	- Comparison not possible
	10	Clinical-SI	Fail	270.0	NA	<u>- Blood</u> (Day -2): NG <u>- Sputum</u> (Day -2): GS: Few GPCP, Few GNR, Few WBCs, Rare GPR, Cx: Heavy NRF <u>- BAL</u> (Day -2): GS: Few WBCs, Rare GPCP, Rare GPR, Rare GNR, Cx: NRF; ND legionella Cx, ND RVP	- Comparison not possible
36	1	No-Suspected-SI	Pass Qualitatively	686.2	Escherichia coli	<u>- Blood</u> (Day -1): NG <u>- Urine (</u> Day -1): Cx: NG - Blood (Day +2): NG	- Plausible pathogen identified
	5	No-Suspected-SI	Pass	362.7	Human herpesvirus 1, 2565		<ul> <li>Microbe of unclear clinical significance</li> </ul>
37	1	No-Suspected-SI	Fail	3188.8	NA	<u>- Blood</u> (Day -2): NG, PCR: CMV ND <u>- Urine (</u> Day -1): Cx: NG <u>- Urine (</u> Day -1): Ag: Legionella ND	- Comparison not possible
	5	No-Suspected-SI	Pass	2792.4	No Organism Reported, 0		<ul> <li>Comparison not possible</li> </ul>
38	1	No-Suspected-SI	Pass	148.7	Staphylococcus epidermidis, 808	<u>- Blood</u> (Day -1): NG <u>- BAL (</u> Day -1): GS: Rare WBCs, GPCP, NRF	- Microbe of unclear clinical significance
	5	No-Suspected-SI	Pass	122.2	Staphylococcus epidermidis, 485		<ul> <li>Microbe of unclear clinical significance</li> </ul>
	10	Micro-SI	Pass	163.7	Enterococcus faecalis, 712	<u>- Blood</u> (Day -2): NG <u>- Urine (</u> Day -2): Cx:	- Concordant

					Prevotella denticola, 170 Lactobacillus gasseri, 157 Prevotella oris, 148	Enterococcus faecalis - <u>BAL (</u> Day -2): GS: Rare WBCs, Rare GPCP, Cx: NRF	
39	1	No-Suspected-SI	Pass	148.6	Rothia mucilaginosa, 157	<u>- Blood</u> (Day -2): NG	<ul> <li>Microbe of unclear clinical significance</li> </ul>
40	1	No-Suspected-SI	Pass	139.7	Human herpesvirus 4, 149		<ul> <li>Microbe of unclear clinical significance</li> </ul>
41	1	No-Suspected-SI	Pass Qualitatively	722.2	Lactobacillus gasseri		<ul> <li>Microbe of unclear clinical significance</li> </ul>
42	1	No-Suspected-SI	Pass	8340.9	Staphylococcus epidermidis, 3036 Human herpesvirus 4, 889 Helicobacter pylori, 345	<u>- Blood</u> (Day -2): NG <u>- Urine (</u> Day -2): Ag: Streptococcus pneumonia & Legionella ND	- Microbe of unclear clinical significance

493 Abbreviations: Not detected (ND); no growth (NG); normal respiratory flora (NRF); gram stain (GS); culture (Cx); gram negative rods (GNRs); gram

494 positive cocci in chains (GPCCH); gram positive cocci in pairs (GPCP); T2 Candida fungal test (T2).

495

496 e-Table 3: Microbial species classifications

Taxon	Class	Anatomic Compartment
Actinomyces graevenitzii	Recognized pathogen	Oral
Actinomyces odontolyticus	Recognized pathogen	Oral
Bacteroides ovatus	Microbe with unclear clinical importance	GI
Bacteroides vulgatus	Microbe with unclear clinical importance	GI
Burkholderia cepacia complex	Recognized pathogen	Respiratory, Nosocomial
Candida parapsilosis	Microbe with unclear clinical importance	Skin, Gl
Candida tropicalis	Microbe with unclear clinical importance	Skin, Gl
Corynebacterium striatum	Microbe with unclear clinical importance	Skin
Enterococcus faecalis	Recognized pathogen	GI
Enterococcus faecium	Recognized pathogen	GI
Escherichia coli	Recognized pathogen	GI
Haemophilus influenzae	Recognized pathogen	Oral
Haemophilus parahaemolyticus	Microbe with unclear clinical importance	Oral
Helicobacter pylori	Microbe with unclear clinical importance	GI
Human herpesvirus 1	Microbe with unclear clinical importance	Unknown
Human herpesvirus 4	Microbe with unclear clinical importance	Unknown

Klebsiella pneumoniae	Recognized pathogen	Oral, GI
Klebsiella variicola	Recognized pathogen	GI
Lactobacillus gasseri	Microbe with unclear clinical importance	GI
Pantoea ananatis	Microbe with unclear clinical importance	Unknown
Pediococcus acidilactici	Microbe with unclear clinical importance	GI
Prevotella bivia	Microbe with unclear clinical importance	Oral
Prevotella denticola	Microbe with unclear clinical importance	Oral
Prevotella oris	Microbe with unclear clinical importance	Oral
Proteus mirabilis	Recognized pathogen	GI
Pseudomonas aeruginosa	Recognized pathogen	GI, Pulmonary, Nosocomial
Raoultella ornithinolytica	Recognized pathogen	GI
Rothia mucilaginosa	Microbe with unclear clinical importance	Oral
Staphylococcus aureus	Recognized pathogen	Skin
Staphylococcus epidermidis	Microbe with unclear clinical importance	Skin
Streptococcus gordonii	Microbe with unclear clinical importance	Oral
Streptococcus infantarius	Microbe with unclear clinical importance	Oral
Streptococcus mitis	Recognized pathogen	Oral, Skin
Streptococcus parasanguinis	Recognized pathogen	Oral
Streptococcus salivarius	Microbe with unclear clinical importance	Oral
Streptococcus sanguinis	Microbe with unclear clinical importance	Oral
Streptococcus thermophilus	Microbe with unclear clinical importance	Oral
Scardovia wiggsiae	Microbe with unclear clinical importance	Oral